Luzhu Biotech braces for make-or-break launch of shingles shot
The company has pared its annual losses but faces high costs and competitive challenges to deliver its voluntary vaccine into a tight market Key Takeaways: The biotech slashed its R&D…
FAST NEWS: Luzhu Biotech repurchases shares
The Latest: Beijing Luzhu Biotechnology Co. Ltd. (2480.HK) announced Monday that it repurchased a combined 1.43 million of the company’s shares on July 12 and 15, after its board authorized…
Loss-making Vaccine Creator Luzhu Aims for IPO Booster Shot
The IPO-bound biotech is still developing its shingles vaccines and other antibody therapies, but the company has spent heavily in recent years on financial productsKey Takeaways:Losses of 1.26 billion yuan…
RELATED ARTICLES
-
Meningitis shot delivers dose of good cheer for CanSino
688185.SHG -
China Merchants Bank falters as economic slowdown wipes out growth
600036.SHG
- Weihai Bank gets government-led year-end capital gift, highlighting its troubles
- Trip.com braces for new era of competition with anti-monopoly probe
- Eye drug maker VivaVision feels the strain in IPO funding dash
